Filing Flows

Filing Flows › Companies › Karyopharm Therapeutics › Cash flow

Karyopharm Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$24.9M in Q2 2026 · −$65.3M over twelve months

Operating cash flow−$24.9M
Free cash flow−$24.9M

Analysis

In Q2 2026, Karyopharm Therapeutics generated −$24.9M of operating cash flow. That is $6.2M less than in Q2 2025 (−$18.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$65.3M; the largest uses were operating cash flow ($65.3M); besides operations, cash came from other financing ($77.6M), other investing ($3.0M); the cash balance rose by $16.2M.

Operating cash flow was −$24.9M against net income of −$67.0M. The largest differences: receivables −$6.5M, accrued liabilities +$3.8M, payables +$3.4M.

Free cash flow

Karyopharm Therapeutics: free cash flow by quarterKaryopharm Therapeutics: free cash flow by quarter−$19.5MQ3 2024−$25.8MQ4 2024−$39.0MQ1 2025−$18.7MQ2 2025−$5.9MQ3 2025−$11.8MQ4 2025−$22.7MQ1 2026−$24.9MQ2 2026
Operating cash flow less capital spending.
Karyopharm Therapeutics: operating cash flow against capital spendingKaryopharm Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$19.5M$0Q3 2024−$25.8M−$53KQ4 2024−$39.0M$0Q1 2025−$18.7M$0Q2 2025−$5.9M$0Q3 2025−$11.8M$0Q4 2025−$22.7M$0Q1 2026−$24.9M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$24.9M, Capital spending $0.

Capital allocation, year by year

Karyopharm Therapeutics: where the cash came from (up) and went (down), by fiscal yearKaryopharm Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$107MFY2021: Shares issued $3.7MFY2021: Capital spending −$212K$3.7MFY2021FY2022: Operating cash flow −$150MFY2022: Shares issued $4.0MFY2022: Capital spending −$118K$4.0MFY2022FY2023: Operating cash flow −$92.7MFY2023: Shares issued $1.1M$1.1MFY2023FY2024: Operating cash flow −$127MFY2024: Net borrowing $83.3MFY2024: Shares issued $1.5MFY2024: Capital spending −$142K$84.8MFY2024FY2025: Operating cash flow −$75.4MFY2025: Net borrowing $12.0MFY2025: Shares issued $761K$12.8MFY2025
Over these 5 years operating cash flow totalled −$552M; the largest uses were operating cash flow ($552M) and capital spending ($472K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$65.1M
Debtnone
Net cash$65.1M
Cash runway12 months

Karyopharm Therapeutics is burning cash: its operations consume cash, a free cash flow of −$65.3M a year at the current rate against $65.1M of cash and investments: a runway of about 12 months before any new financing.

Where the cash came from and went

Karyopharm Therapeutics: sources (+) and uses (−) of cash, Q2 2026Karyopharm Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$35.9MOperating cash flow−$24.9MOther investing−$10.0MOther financing−$898KExchange rates−$4K
Karyopharm Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Karyopharm Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$77.6MOperating cash flow−$65.3MCash drawn (+) / kept (−)−$16.2MOther investing$3.0MShares issued$979KExchange rates$5K

From profit to cash

Karyopharm Therapeutics: net income to operating cash flow, Q2 2026Karyopharm Therapeutics: net income to operating cash flow, Q2 2026Net income−$67.0MDepreciation & amortization−$3KStock-based pay$1.9MReceivables−$6.5MInventory−$395KPayables$3.4MAccrued liabilities$3.8MPrepaid and other assets$1.1MOperating cash flow−$24.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$24.9M———$35.9M−$24.9M
Q1 2026−$22.7M——$20.2M−$30.3M−$22.7M
Q4 2025−$11.8M—$12.2M$405K−$22.9M−$11.8M
Q3 2025−$5.9M———$1.1M−$5.9M
Q2 2025−$18.7M———$48K−$18.7M
Q1 2025−$39.0M———$23.7M−$39.0M
Q4 2024−$25.8M$53K—$680K$10.4M−$25.8M
Q3 2024−$19.5M———$11.9M−$19.5M

Karyopharm Therapeutics: income statement and cash flow

Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%. The chart follows the revenue to costs, profit and cash.

Karyopharm Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.